Influence of bromopride in the prophylaxis of nausea associated with fluorescein angiography.
OBJECTIVE
To determine the efficacy of bromopride in the prophylaxis of nausea during fluorescein angiography, when compared with a placebo.


METHODS
The study was a double-masked random clinical trial, between December of 2004 and April of 2005. Examinations were performed with 20% intravenous fluorescein sodium in a single dose of 2.5 ml. The patients were divided into two groups: group 1, patients who received a 2 ml intravenous dose of 5 mg/ml bromopride and group 2, patients who received a 2 ml intravenous dose of 0.9% sodium chloride (placebo), both 20 minutes before the dye injection. Cases of nausea were observed during and after the examination.


RESULTS
352 patients were enrolled, 176 in each group. Cases of nausea were observed in 12 (6.8%) patients of the bromopride group and in 11 (6.3%) patients of the placebo group (p<0.829 - relative risk=1.05).


CONCLUSIONS
Bromopride did not prevent the occurrence of nausea in fluorescein angiography, when compared with a placebo.
Lira
Rodrigo Pessoa Cavalcanti
RP
Universidade Estadual de Campinas, Campinas, SP, Brazil. rodrigopclira@hotmail.com
Moraes
Luiz Felipe Lynch de
LF
Oliveira Júnior
Mauro de
Md
Melo
Antônio Luiz Barbosa de
AL
Vasconcelos
Mirelle Souza Leão
MS
D000932:Antiemetics / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005451:Fluorescein Angiography / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D009325:Nausea / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome
D000932:Antiemetics; C013855:bromopride; D008787:Metoclopramide